XL MDM2

Enumeration Probe

Order Number
D-5047-100-OG
Package Size
100 µl (10 Tests)
Labels
  
Chromosome
12
Regulatory Status
IVDD

IVDR Certification

This probe is IVDR-certified in compliance with the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR).

MetaSystems Probes has already certified a large part of its portfolio, according to IVDR. For organizational reasons, we currently provide only the IVDD product.

Please use the switch to change to the IVDR product.

IVDDIVDRDiscover all IVDR-certified products

Product Description

XL MDM2

XL MDM2 consists of an orange-labeled probe hybridizing to the MDM2 gene region at 12q15 and a green-labeled probe hybridizing to the centromere of chromosome 12.

Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.

Need assistance or a quote?

Clinical Details

The tumor suppressor gene TP53 is a key regulator in the cell cycle and is involved in apoptosis, genomic stability and angiogenesis. Inactivation of TP53 function prevents the antiproliferative effect and contributes to the development of many types of cancer. Several mechanisms of TP53 loss of function are known such as gene mutations, interaction of p53 with viral proteins and association of p53 with the MDM2 oncoprotein. MDM2 is an ubiquitin ligase negatively regulating p53. MDM2 is amplified in about 7% of all human cancers with the highest frequency of about 20% in soft tissue tumors. MDM2 might also have p53-independent transforming capabilities. Well-differentiated liposarcomas/atypical lipomatous tumors (WDL-ALT) and dedifferentiated liposarcomas are among the most common soft tissue tumors in adults. Both entities share the same genetic aberration, an amplification of the chromosomal region including MDM2. WDL-ALT and benign lipomatous tumors can be morphologically similar and a clear assignment based on histological features might be difficult. The analysis of the MDM2 amplification status by FISH is considered as a useful technique for the differential diagnosis of WDL-ALT and benign lipomatous tumors since benign lesions do not harbor MDM2 amplifications. Furthermore, MDM2 overexpression has been reported to be a potential cause of p53 dysfunction in chronic lymphoblastic leukemia.

Clinical Applications

  • Chronic Lymphocytic Leukemia (CLL)
Need assistance or a quote?

Images

XL MDM2

XL MDM2 hybridized to lymphocytes. Two normal interphases and one normal metaphase are shown.

Need assistance or a quote?

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
Two green (2G) and three orange (3O) signals resulting from gain of one orange signal.

Need assistance or a quote?

Literature

  • Haidar et al (1997) Am J Hematol 54:189-195
  • Momand et al (1998) Nucleic Acids Res 26:3453-3459
  • Weaver et al (2008) Mod Pathol 21:943-949

Downloads

News

IVDR Certification

MetaSystems Probes has received IVDR certification for our initial 26 fluorescence in situ hybridization (FISH) probes from the notified body, BSI. Achieving this milestone was not without its challenges, and we are delighted to have accomplished IVDR certification for this probe set at an early stage.

IVDR Certification

New Probes Catalog is Online!

 

MetaSystems Probes is pleased to announce the new catalog including new and innovative products and supporting information. A PDF version of the new catalog is available for download here.

New Probes Catalog is Online!